标题
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
作者
关键词
-
出版物
OncoImmunology
Volume 6, Issue 12, Pages e1371896
出版商
Informa UK Limited
发表日期
2017-08-31
DOI
10.1080/2162402x.2017.1371896
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- iRECIST: A clarification of tumour response assessment in the immunotherapy era
- (2017) Charles Ferté et al. EUROPEAN JOURNAL OF CANCER
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies
- (2017) Anthony F. Daniyan et al. Nature Reviews Clinical Oncology
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
- (2017) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted therapies for renal cell carcinoma
- (2017) Edwin M. Posadas et al. Nature Reviews Nephrology
- Vaccine-based immunotherapeutic approaches to gliomas and beyond
- (2017) Michael Weller et al. Nature Reviews Neurology
- Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials
- (2017) Chris Blick et al. Nature Reviews Urology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma
- (2017) Sara J. McKee et al. Cancer Immunology Research
- Barriers to Radiation-Induced In Situ Tumor Vaccination
- (2017) Erik Wennerberg et al. Frontiers in Immunology
- Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity
- (2017) Zuqiang Liu et al. OncoImmunology
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory
- (2017) Nick M. Durham et al. Journal for ImmunoTherapy of Cancer
- Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
- (2016) Lauren CJ Baker et al. BRITISH JOURNAL OF CANCER
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells
- (2016) Ilaria Marigo et al. CANCER CELL
- 4-1BB agonism: adding the accelerator to cancer immunotherapy
- (2016) Cariad Chester et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
- (2016) Rachel E. Sanborn et al. CANCER RESEARCH
- Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
- (2016) Shin Foong Ngiow et al. CANCER RESEARCH
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
- (2016) Xiaohong Wang et al. CANCER RESEARCH
- Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
- (2016) Ashley E. Mahne et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future
- (2016) A. Muntasell et al. CLINICAL CANCER RESEARCH
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Soluble OX40L favors tumor rejection in CT26 colon carcinoma model
- (2016) Ekaterina O. Serebrovskaya et al. CYTOKINE
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-CD137 cancer immunotherapy
- (2016) Amani Makkouk et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
- (2016) Joseph M. Ryan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Novel anti-angiogenic therapeutic strategies in colorectal cancer
- (2016) M. Tampellini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Therapeutic targeting of CD70 and CD27
- (2016) Harald Wajant EXPERT OPINION ON THERAPEUTIC TARGETS
- Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
- (2016) Gregory L. Beatty et al. Expert Review of Anticancer Therapy
- The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account
- (2016) Thomas Hünig FEBS Journal
- Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
- (2016) Frank A. Schildberg et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
- (2016) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Combine and conquer: challenges for targeted therapy combinations in early phase trials
- (2016) Juanita S. Lopez et al. Nature Reviews Clinical Oncology
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- The cancer vaccine resurgence
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
- (2016) Yufang Shi et al. NATURE REVIEWS DRUG DISCOVERY
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy
- (2016) I. Melero et al. Cancer Discovery
- Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy
- (2016) Chang-Ae Shin et al. Oncotarget
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
- (2016) L. Galluzzi et al. Cancer Immunology Research
- Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
- (2016) G. Fromm et al. Cancer Immunology Research
- Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells
- (2016) Diego Sánchez-Martínez et al. Frontiers in Immunology
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications
- (2016) Erika Vacchelli et al. OncoImmunology
- Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity
- (2016) Leonid Dubrovsky et al. OncoImmunology
- The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy
- (2016) Mario Roselli et al. OncoImmunology
- Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop
- (2016) Roch Houot et al. OncoImmunology
- Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer
- (2016) Eleonora Timperi et al. OncoImmunology
- Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization
- (2016) Fan Zhang et al. OncoImmunology
- Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment
- (2016) Jamie A. Saxon et al. OncoImmunology
- Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity
- (2016) Fernando Souza-Fonseca-Guimaraes et al. OncoImmunology
- CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells
- (2016) Tiphaine Parrot et al. OncoImmunology
- The clinical impact of ICOS signal in colorectal cancer patients
- (2016) Yan Zhang et al. OncoImmunology
- Polyfunctional Melan-A-specific tumor-reactive CD8+T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS
- (2016) Ornella Franzese et al. OncoImmunology
- Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor
- (2016) Valentino Le Noci et al. OncoImmunology
- CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth
- (2016) Sakthi Rajendran et al. OncoImmunology
- Chemotherapy and immunotherapy: A close interplay to fight cancer?
- (2016) Aurélie Hanoteau et al. OncoImmunology
- Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
- (2016) Nikolai Siebert et al. OncoImmunology
- Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
- (2016) Aitziber Buqué et al. OncoImmunology
- Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format
- (2016) Sina Fellermeier et al. OncoImmunology
- CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
- (2016) Guang-Tao Yu et al. OncoImmunology
- Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?
- (2016) Sandra Demaria et al. Journal for ImmunoTherapy of Cancer
- Mogamulizumab: 2 birds, 1 stone
- (2015) R. A. Wilcox BLOOD
- Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework
- (2015) Rienk Offringa et al. CANCER CELL
- Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
- (2015) Ann L. White et al. CANCER CELL
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
- (2015) David L. Bajor et al. CANCER RESEARCH
- Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2R null Immunodeficient Mice
- (2015) M. F. Sanmamed et al. CANCER RESEARCH
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- ICOS:ICOS-Ligand Interaction Is Required for Type 2 Innate Lymphoid Cell Function, Homeostasis, and Induction of Airway Hyperreactivity
- (2015) Hadi Maazi et al. IMMUNITY
- CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+T Cells with Antitumor Activity
- (2015) Ilseyar Akhmetzyanova et al. JOURNAL OF IMMUNOLOGY
- Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+Regulatory T Cells Are Depleted
- (2015) Young H. Kim et al. JOURNAL OF IMMUNOLOGY
- Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
- (2015) Encouse B Golden et al. LANCET ONCOLOGY
- CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
- (2015) Philippe A Cassier et al. LANCET ONCOLOGY
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
- (2015) Luis Fayad et al. LEUKEMIA & LYMPHOMA
- Glucocorticoid-induced tumor necrosis factor receptor–related protein co-stimulation facilitates tumor regression by inducing IL-9–producing helper T cells
- (2015) Il-Kyu Kim et al. NATURE MEDICINE
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- CD70: An emerging target in cancer immunotherapy
- (2015) J. Jacobs et al. PHARMACOLOGY & THERAPEUTICS
- Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
- (2015) Bettina Weigelin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
- (2015) Miguel F. Sanmamed et al. SEMINARS IN ONCOLOGY
- Combination of Radiotherapy and Immune Checkpoint Inhibitors
- (2015) Karsten A. Pilones et al. SEMINARS IN RADIATION ONCOLOGY
- GITR subverts Foxp3+ Tregs to boost Th9 immunity through regulation of histone acetylation
- (2015) Xiang Xiao et al. Nature Communications
- Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
- (2015) A. R. Sanchez-Paulete et al. Cancer Discovery
- Experimental drug that injured UK volunteers resumes in human trials
- (2015) O. Dyer BMJ-British Medical Journal
- Experimental drug that injured UK volunteers resumes in human trials
- (2015) O. Dyer BMJ-British Medical Journal
- Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
- (2015) A. Zippelius et al. Cancer Immunology Research
- Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
- (2015) D. J. DiLillo et al. Cancer Immunology Research
- Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
- (2015) Jitka Fucikova et al. Frontiers in Immunology
- Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma
- (2015) Melanie Ruf et al. OncoImmunology
- Functional expression of CD137 (4-1BB) on T helper follicular cells
- (2015) Carlos Alfaro et al. OncoImmunology
- SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer
- (2015) Abhishek K. Srivastava et al. OncoImmunology
- Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors
- (2015) José Yélamos et al. OncoImmunology
- GITR agonist enhances vaccination responses in lung cancer
- (2015) Li X Zhu et al. OncoImmunology
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
- (2015) Kristina Iribarren et al. OncoImmunology
- Restoration of defective cross-presentation in tumors by gemcitabine
- (2015) Alison M McDonnell et al. OncoImmunology
- Trial watch: Naked and vectored DNA-based anticancer vaccines
- (2015) Norma Bloy et al. OncoImmunology
- Delineating CSF-1-dependent regulation of myeloid cell diversity in tumors
- (2015) Amy-Jo Casbon et al. OncoImmunology
- Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma
- (2015) Yusuke Sato et al. OncoImmunology
- Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
- (2015) Blanca Homet Moreno et al. OncoImmunology
- PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
- (2015) Tong Seng Lim et al. OncoImmunology
- A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development
- (2015) Oana Draghiciu et al. OncoImmunology
- Kick-starting the cancer-immunity cycle by targeting CD40
- (2015) P Ellmark et al. OncoImmunology
- Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
- (2015) De-Kuan Chang et al. OncoImmunology
- Metabolic tug-of-war in tumors results in diminished T cell antitumor immunity
- (2015) Wan-Chen Cheng et al. OncoImmunology
- Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells
- (2015) Joyce M. van Dodewaard-de Jong et al. OncoImmunology
- GITR drives TH9-mediated antitumor immunity
- (2015) Il-Kyu Kim et al. OncoImmunology
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications
- (2015) Erika Vacchelli et al. OncoImmunology
- Reducing toxicity of 4–1BB costimulation: targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates
- (2015) B Schrand et al. OncoImmunology
- Trial Watch: Peptide-based anticancer vaccines
- (2015) Jonathan Pol et al. OncoImmunology
- Trial Watch—Immunostimulation with cytokines in cancer therapy
- (2015) Erika Vacchelli et al. OncoImmunology
- Human NK cells activated by EBV+lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells
- (2015) Diego Sánchez-Martínez et al. OncoImmunology
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
- (2015) Aitziber Buqué et al. OncoImmunology
- Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark
- (2015) Guido Kroemer et al. OncoImmunology
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
- (2015) Jonathan Pol et al. OncoImmunology
- GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cellsex vivo
- (2015) Alexander Pedroza-Gonzalez et al. OncoImmunology
- Immunotherapy for cancer in the central nervous system: Current and future directions
- (2015) David C. Binder et al. OncoImmunology
- Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neuby human dendritic cells
- (2015) Renato B Baleeiro et al. OncoImmunology
- Trial Watch—Oncolytic viruses and cancer therapy
- (2015) Jonathan Pol et al. OncoImmunology
- Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma
- (2015) Pierre Combe et al. OncoImmunology
- Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients
- (2015) Audrey Hennequin et al. OncoImmunology
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
- (2015) Hanren Dai et al. OncoImmunology
- Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
- (2015) Annie A Wu et al. OncoImmunology
- Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
- (2015) Venky Ramakrishna et al. Journal for ImmunoTherapy of Cancer
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
- (2015) Stefanie N. Linch et al. Frontiers in Oncology
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes
- (2014) L Liljenfeldt et al. CANCER GENE THERAPY
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
- (2014) R. S. Dronca et al. CLINICAL CANCER RESEARCH
- The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity
- (2014) S. M. Mangsbo et al. CLINICAL CANCER RESEARCH
- OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
- (2014) Yannick Bulliard et al. IMMUNOLOGY AND CELL BIOLOGY
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- ICOS/ICOSL Interaction Is Required for CD4+ Invariant NKT Cell Function and Homeostatic Survival
- (2014) O. Akbari et al. JOURNAL OF IMMUNOLOGY
- Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
- (2014) Ann L. White et al. JOURNAL OF IMMUNOLOGY
- OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells To Exit Quiescence
- (2014) Sarah L. Buchan et al. JOURNAL OF IMMUNOLOGY
- T–B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction
- (2014) Dan Liu et al. NATURE
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy
- (2014) B. Schrand et al. Cancer Immunology Research
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
- (2014) Richard G Everson et al. Journal for ImmunoTherapy of Cancer
- The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
- (2014) Joanne Leung et al. Immune Network
- FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
- (2013) Ann L. White et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
- (2013) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
- (2013) A. Marabelle et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- The CD70-CD27 Axis, a New Brake in the T Helper 17 Cell Response
- (2013) Xiaohu Wang et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD70 Is Downregulated by Interaction with CD27
- (2013) M. Kuka et al. JOURNAL OF IMMUNOLOGY
- Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice
- (2013) L.-Z. He et al. JOURNAL OF IMMUNOLOGY
- Diffuse large B-cell lymphoma—treatment approaches in the molecular era
- (2013) Mark Roschewski et al. Nature Reviews Clinical Oncology
- New checkpoint inhibitors ride the immunotherapy tsunami
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Metabolic targets for cancer therapy
- (2013) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Proposed mechanisms of action for prostate cancer vaccines
- (2013) Sean M. Geary et al. Nature Reviews Urology
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo
- (2013) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tolerance and exhaustion: defining mechanisms of T cell dysfunction
- (2013) Andrea Schietinger et al. TRENDS IN IMMUNOLOGY
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
- (2013) D. A. Schaer et al. Cancer Immunology Research
- The CD27 and CD70 Costimulatory Pathway Inhibits Effector Function of T Helper 17 Cells and Attenuates Associated Autoimmunity
- (2012) Jonathan M. Coquet et al. IMMUNITY
- Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells
- (2012) S. P. Bak et al. JOURNAL OF IMMUNOLOGY
- CD70 Deficiency Impairs Effector CD8 T Cell Generation and Viral Clearance but Is Dispensable for the Recall Response to Lymphocytic Choriomeningitis Virus
- (2012) I. Munitic et al. JOURNAL OF IMMUNOLOGY
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
- (2012) Andres Forero-Torres et al. LEUKEMIA & LYMPHOMA
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- Trial Watch: Monoclonal antibodies in cancer therapy
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
- (2011) Giuseppe Nocentini et al. BRITISH JOURNAL OF PHARMACOLOGY
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
- (2011) Jens Rüter et al. CANCER BIOLOGY & THERAPY
- Matrix Metalloproteinase-2 Conditions Human Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12- and OX40L-Dependent Pathway
- (2011) Emmanuelle Godefroy et al. CANCER CELL
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes
- (2011) A. Palazon et al. CANCER RESEARCH
- Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
- (2011) J. Fucikova et al. CANCER RESEARCH
- Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease
- (2011) Robert C. Rickert et al. IMMUNOLOGICAL REVIEWS
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)
- (2010) Tyler R Simpson et al. CURRENT OPINION IN IMMUNOLOGY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
- (2010) Anusha Kalbasi et al. JOURNAL OF IMMUNOTHERAPY
- Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells
- (2010) Drew J. Roberts et al. JOURNAL OF IMMUNOTHERAPY
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Targeting Toll-like receptors: emerging therapeutics?
- (2010) Elizabeth J. Hennessy et al. NATURE REVIEWS DRUG DISCOVERY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
- (2009) Erica L Carpenter et al. Journal of Translational Medicine
- OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
- (2008) M. J. Gough et al. CANCER RESEARCH
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started